(Q33401123)

English

Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase I clinical trial

0 references

pancreatic cancer

1 reference

based on heuristic

inferred from title

Tanios Bekaii-Saab

5

object named as

Tanios Bekaii-Saab

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Allyson J Ocean

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kenneth L Pennington

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michael J Guarino

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Arif Sheikh

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Aldo N Serafini

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Daniel Lee

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Max W Sung

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Seza A Gulec

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Stanley J Goldsmith

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Timothy Manzone

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michael Holt

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Bert H O'Neil

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Nathan Hall

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Alberto J Montero

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

John Kauh

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

David V Gold

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Heather Horne

18

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

William A Wegener

19

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

David M Goldenberg

20

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

8 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

118

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

5497-5506

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215160

21 June 2018

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215160

21 June 2018

Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215160

21 June 2018

Cancer radioimmunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215160

21 June 2018

Detection of early-stage pancreatic adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215160

21 June 2018

High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215160

21 June 2018

Pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215160

21 June 2018

Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215160

21 June 2018

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215160

21 June 2018

Combined modality therapy of gemcitabine and radiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215160

21 June 2018

A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215160

21 June 2018

Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215160

21 June 2018

Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215160

21 June 2018

A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215160

21 June 2018

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215160

21 June 2018

Bone marrow dosimetry for radioimmunotherapy: theoretical considerations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215160

21 June 2018

Characterization of cluster 13: the epithelial/carcinoma antigen recognized by MAb RS7.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215160

21 June 2018

PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27592

21 January 2018

Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27592

21 January 2018

Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27592

21 January 2018

Evaluation of lymph nodes with RECIST 1.1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27592

21 January 2018

90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4215160

31 October 2018

MIRDOSE: personal computer software for internal dose assessment in nuclear medicine

1 reference

https://pubmed.ncbi.nlm.nih.gov/22569804

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled monoclonal antibody PAM4

1 reference

https://pubmed.ncbi.nlm.nih.gov/22569804

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22569804

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.27592

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33401123&oldid=1980512268"